Engineering novel Lec1 glycosylation mutants in CHO-DUKX cells: Molecular insights and effector modulation of N-acetylglucosaminyltransferase I

Biotechnology and Bioengineering

Volumn 109, Issue 7, 2012, Pages 1723-1734

  Zhong, Xiaotian ^a   Cooley, Cecilia ^a   Seth, Nilufer ^a   Juo, Z Sean ^a   Presman, Ella ^a,b   Resendes, Nicole ^a   Kumar, Ravi ^a,b   Allen, Martin ^a   Mosyak, Lidia ^a   Stahl, Mark ^a   Somers, Will ^a   Kriz, Ronald ^a  

^a PFIZER INC   (United States)

^b Acceleron Pharma Inc   (United States)

Author keywords

Antibody dependent cellular cytotoxicity (ADCC); Complement dependent cytotoxicity (CDC); Glycosylation mutant allele; GnTI; Loss of function sense mutation; Man 5GlcNAc 2 glycan

Indexed keywords

ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITIES; COMPLEMENT-DEPENDENT CYTOTOXICITIES; GNTI; LOSS-OF-FUNCTION SENSE MUTATION; MAN 5GLCNAC 2 GLYCAN; MUTANT ALLELES;

ANTIBODIES; CARBOHYDRATES; CELL MEMBRANES; DNA SEQUENCES; ESTERIFICATION; GLYCOSYLATION; HYDROGEN BONDS; MANGANESE; MANGANESE COMPOUNDS; SUBSTRATES;

CELL ENGINEERING;

ADVANCED GLYCATION END PRODUCT; CD20 ANTIBODY; GLYCAN; GLYCOPROTEIN; LECTIN; MANNOSE OLIGOSACCHARIDE; N ACETYLGLUCOSAMINYLTRANSFERASE; N ACETYLGLUCOSAMINYLTRANSFERASE I; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BINDING SITE; CATALYSIS; CELL CLONE; CELL ENGINEERING; CELL LINE; CELL MUTANT; CHEMICAL MUTAGENESIS; CHO CELL; CHO DUKX LEC1 CELL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME GLYCOSYLATION; ENZYME KINETICS; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; LOSS OF FUNCTION MUTATION; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CHO CELLS; CLONE CELLS; CRICETINAE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; N-ACETYLGLUCOSAMINYLTRANSFERASES; OLIGOSACCHARIDES; PROTEIN ENGINEERING; RABBITS; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT;

ORYCTOLAGUS CUNICULUS;

EID: 84863405424     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24448     Document Type: Article

References (79)

1. Aricescu AR, Lu W, Jones EY. 2006. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr 62(Pt 10): 1243- 1250.
2. Arlaud GJ, Thielens NM. 2010. Complement: Classical and lectin pathways. Encyclopedia of life sciences. Chichester: John Wiley & Sons, Ltd.
3. Arquint M, Roder J, Chia LS, Down J, Wilkinson D, Bayley H, Braun P, Dunn R. 1987. Molecular cloning and primary structure of myelin-associated glycoprotein. Proc Natl Acad Sci USA 84(2): 600- 604.
4. Bagshawe KD. 1995. Antibody-directed enzyme prodrug therapy for cancer: Its theoretical basis and application. Mol Med Today 1(9): 424- 431.
5. Boyd PN, Lines AC, Patel AK. 1995. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 32(17-18): 1311- 1318.
6. Brady RO, Barton NW. 1994. Enzyme replacement therapy for Gaucher disease: Critical investigations beyond demonstration of clinical efficacy. Biochem Med Metab Biol 52(1): 1- 9.
7. Brandli AW. 1991. Mammalian glycosylation mutants as tools for the analysis and reconstitution of protein transport. Biochem J 276(Pt 1): 1- 12.
8. Chang VT, Crispin M, Aricescu AR, Harvey DJ, Nettleship JE, Fennelly JA, Yu C, Boles KS, Evans EJ, Stuart DI, Dwek, RA, Jones, EY, Owens, RJ, Davis, SJ. 2007. Glycoprotein structural genomics: Solving the glycosylation problem. Structure 15(3): 267- 273.
9. Chen W, Stanley P. 2003. Five Lec1 CHO cell mutants have distinct Mgat1 gene mutations that encode truncated N-acetylglucosaminyltransferase I. Glycobiology 13(1): 43- 50.
10. Chen J, Moloney DJ, Stanley P. 2001a. Fringe modulation of Jagged1-induced Notch signaling requires the action of beta 4galactosyltransferase-1. Proc Natl Acad Sci USA 98(24): 13716- 13721.
11. Chen W, Unligil UM, Rini JM, Stanley P. 2001b. Independent Lec1A CHO glycosylation mutants arise from point mutations in N-acetylglucosaminyltransferase I that reduce affinity for both substrates. Molecular consequences based on the crystal structure of GlcNAc-TI. Biochemistry 40(30): 8765- 8772.
12. Crispin M, Harvey DJ, Chang VT, Yu C, Aricescu AR, Jones EY, Davis SJ, Dwek RA, Rudd PM. 2006. Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. Glycobiology 16(8): 748- 756.
13. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. 2001. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 74(4): 288- 294.
14. Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, Amora R, Hocking TD, Zhang L, Rebar EJ, et al. 2008. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 26(6): 702- 708.
15. Ferrara C, Brunker P, Suter T, Moser S, Puntener U, Umana P. 2006. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 93(5): 851- 861.
16. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. 2011. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21(7): 949- 959.
17. Gordon RD, Sivarajah P, Satkunarajah M, Ma D, Tarling CA, Vizitiu D, Withers SG, Rini JM. 2006. X-ray crystal structures of rabbit N-acetylglucosaminyltransferase I (GnT I) in complex with donor substrate analogues. J Mol Biol 360(1): 67- 79.
18. Gottlieb C, Baenziger J, Kornfeld S. 1975. Deficient uridine diphosphate-N-acetylglucosamine:glycoprotein N-acetylglucosaminyltransferase activity in a clone of Chinese hamster ovary cells with altered surface glycoproteins. J Biol Chem 250(9): 3303- 3309.
19. Haltiwanger RS. 2002. Regulation of signal transduction pathways in development by glycosylation. Curr Opin Struct Biol 12(5): 593- 598.
20. Hodoniczky J, Zheng YZ, James DC. 2005. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21(6): 1644- 1652.
21. Hoppe H. 2000. Cerezyme-recombinant protein treatment for Gaucher's disease. J Biotechnol 76(2-3): 259- 261.
22. Hull E, Sarkar M, Spruijt MP, Hoppener JW, Dunn R, Schachter H. 1991. Organization and localization to chromosome 5 of the human UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1, 2-N-acetylglucosaminyltransferase I gene. Biochem Biophys Res Commun 176(2): 608- 615.
23. Imai-Nishiya H, Mori K, Inoue M, Wakitani M, Iida S, Shitara K, Satoh M. 2007. Double knockdown of alpha1, 6-fucosyltransferase (FUT8) and GDP-mannose 4, 6-dehydratase (GMD) in antibody-producing cells: A new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol 7: 84.
24. Ioffe E, Stanley P. 1994. Mice lacking N-acetylglucosaminyltransferase I activity die at mid-gestation, revealing an essential role for complex or hybrid N-linked carbohydrates. Proc Natl Acad Sci USA 91(2): 728- 732.
25. Jefferis R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8(3): 226- 234.
26. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. 2007. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 17(1): 104- 118.
27. Kaneko Y, Nimmerjahn F, Ravetch JV. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787): 670- 673.
28. Kogelberg H, Tolner B, Sharma SK, Lowdell MW, Qureshi U, Robson M, Hillyer T, Pedley RB, Vervecken W, Contreras R, et al. 2007. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. Glycobiology 17(1): 36- 45.
29. Kornfeld R, Kornfeld S. 1985. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54: 631- 664.
30. Kumar R, Yang J, Larsen RD, Stanley P. 1990. Cloning and expression of N-acetylglucosaminyltransferase I, the medial Golgi transferase that initiates complex N-linked carbohydrate formation. Proc Natl Acad Sci USA 87(24): 9948- 9952.
31. Kumar R, Yang J, Eddy RL, Byers MG, Shows TB, Stanley P. 1992. Cloning and expression of the murine gene and chromosomal location of the human gene encoding N-acetylglucosaminyltransferase I. Glycobiology 2(4): 383- 393.
32. Leader KA, Kumpel BM, Hadley AG, Bradley BA. 1991. Functional interactions of aglycosylated monoclonal anti-D with Fc gamma RI+ and Fc gamma RIII+ cells. Immunology 72(4): 481- 485.
33. Leatherbarrow RJ, Rademacher TW, Dwek RA, Woof JM, Clark A, Burton DR, Richardson N, Feinstein A. 1985. Effector functions of a monoclonal aglycosylated mouse IgG2a: Binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol Immunol 22(4): 407- 415.
34. Lin AI, Philipsberg GA, Haltiwanger RS. 1994. Core fucosylation of high-mannose-type oligosaccharides in GlcNAc transferase I-deficient (Lec1) CHO cells. Glycobiology 4(6): 895- 901.
35. Longmore GD, Schachter H. 1982. Product-identification and substrate-specificity studies of the GDP-L-fucose:2-acetamido-2-deoxy-beta-D-glucoside (FUC goes to AsN-linked GlcNAc) 6-alpha-L-fucosyltransferase in a Golgi-rich fraction from porcine liver. Carbohydr Res 100: 365- 392.
36. Malhotra R, Sim RB. 1995. Collectins and viral infection. Trends Microbiol 3(6): 240- 244.
37. Malphettes L, Freyvert Y, Chang J, Liu PQ, Chan E, Miller JC, Zhou Z, Nguyen T, Tsai C, Snowden AW, et al. 2010. Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. Biotechnol Bioeng 106(5): 774- 783.
38. Metzler M, Gertz A, Sarkar M, Schachter H, Schrader JW, Marth JD. 1994. Complex asparagine-linked oligosaccharides are required for morphogenic events during post-implantation development. EMBO J 13(9): 2056- 2065.
39. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh M, Kato K. 2011. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 16(11): 1071- 1080.
40. Moloney DJ, Panin VM, Johnston SH, Chen J, Shao L, Wilson R, Wang Y, Stanley P, Irvine KD, Haltiwanger RS, et al. 2000. Fringe is a glycosyltransferase that modifies Notch. Nature 406(6794): 369- 375.
41. Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, Wakitani M, Yamano K, Imai H, Kanda Y, Niwa R, Iida S, Uchida K, et al. 2004. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 88(7): 901- 908.
42. Natsume A, Niwa R, Satoh M. 2009. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther 3: 7- 16.
43. Nishikawa Y, Pegg W, Paulsen H, Schachter H. 1988. Control of glycoprotein synthesis. Purification and characterization of rabbit liver UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1, 2-N-acetylglucosaminyltransferase I. J Biol Chem 263(17): 8270- 8281.
44. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. 2004. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64(6): 2127- 2133.
45. Omasa T, Onitsuka M, Kim WD. 2010. Cell engineering and cultivation of Chinese hamster ovary (CHO) cells. Curr Pharm Biotechnol 11(3): 233- 240.
46. Opat AS, Puthalakath H, Burke J, Gleeson PA. 1998. Genetic defect in N-acetylglucosaminyltransferase I gene of a ricin-resistant baby hamster kidney mutant. Biochem J 336(Pt 3): 593- 598.
47. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, et al. 2008. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26(7): 808- 816.
48. Pownall S, Kozak CA, Schappert K, Sarkar M, Hull E, Schachter H, Marth JD. 1992. Molecular cloning and characterization of the mouse UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1, 2-N-acetylglucosaminyltransferase I gene. Genomics 12(4): 699- 704.
49. Puthalakath H, Burke J, Gleeson PA. 1996. Glycosylation defect in Lec1 Chinese hamster ovary mutant is due to a point mutation in N-acetylglucosaminyltransferase I gene. J Biol Chem 271(44): 27818- 27822.
50. Rasmussen B, Davis R, Thomas J, Reddy P. 1998. Isolation, characterization and recombinant protein expression in Veggie-CHO: A serum-free CHO host cell line. Cytotechnology 28(1-3): 31- 42.
51. Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, Holmes MC, Guschin D, Waite A, Miller JC, et al. 2008. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci USA 105(15): 5809- 5814.
52. Sarkar M, Hull E, Nishikawa Y, Simpson RJ, Moritz RL, Dunn R, Schachter H. 1991. Molecular cloning and expression of cDNA encoding the enzyme that controls conversion of high-mannose to hybrid and complex N-glycans: UDP-N-acetylglucosamine: Alpha-3-D-mannoside beta-1, 2-N-acetylglucosaminyltransferase I. Proc Natl Acad Sci USA 88(1): 234- 238.
53. Sarkar M, Pagny S, Unligil U, Joziasse D, Mucha J, Glossl J, Schachter H. 1998. Removal of 106 amino acids from the N-terminus of UDP-GlcNAc: Alpha-3-D-mannoside beta-1, 2-N-acetylglucosaminyltransferase I does not inactivate the enzyme. Glycoconj J 15(2): 193- 197.
54. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44(7): 1524- 1534.
55. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277(30): 26733- 26740.
56. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278(5): 3466- 3473.
57. Siminovitch L. 1976. On the nature of hereditable variation in cultured somatic cells. Cell 7(1): 1- 11.
58. Sinacore MS, Drapeau D, Adamson SR. 2000. Adaptation of mammalian cells to growth in serum-free media. Mol Biotechnol 15(3): 249- 257.
59. Sondermann P, Huber R, Oosthuizen V, Jacob U. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406(6793): 267- 273.
60. Stanley P. 1981. Selection of specific wheat germ agglutinin-resistant (WgaR) phenotypes from Chinese hamster ovary cell populations containing numerous lecR genotypes. Mol Cell Biol 1(8): 687- 696.
61. Stanley P. 1984. Glycosylation mutants of animal cells. Annu Rev Genet 18: 525- 552.
62. Stanley P. 1989. Chinese hamster ovary cell mutants with multiple glycosylation defects for production of glycoproteins with minimal carbohydrate heterogeneity. Mol Cell Biol 9(2): 377- 383.
63. Stanley P, Narasimhan S, Siminovitch L, Schachter H. 1975. Chinese hamster ovary cells selected for resistance to the cytotoxicity of phytohemagglutinin are deficient in a UDP-N-acetylglucosamine-glycoprotein N-acetylglucosaminyltransferase activity. Proc Natl Acad Sci USA 72(9): 3323- 3327.
64. Turner MW. 1996. The lectin pathway of complement activation. Res Immunol 147(2): 110- 115.
65. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. 1999. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2): 176- 180.
66. Unligil UM, Zhou S, Yuwaraj S, Sarkar M, Schachter H, Rini JM. 2000. X-ray crystal structure of rabbit N-acetylglucosaminyltransferase I: Catalytic mechanism and a new protein superfamily. EMBO J 19(20): 5269- 5280.
67. Van den Steen P, Rudd PM, Dwek RA, Opdenakker G. 1998. Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol 33(3): 151- 208.
68. Van Patten SM, Hughes H, Huff MR, Piepenhagen PA, Waire J, Qiu H, Ganesa C, Reczek D, Ward PV, Kutzko JP, et al. 2007. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 17(5): 467- 478.
69. Varki A. 1993. Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3(2): 97- 130.
70. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME. 2009. Essentials of glycobiology, 2nd edition. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
71. Voynow JA, Kaiser RS, Scanlin TF, Glick MC. 1991. Purification and characterization of GDP-L-fucose-N-acetyl beta-D-glucosaminide alpha 1, 6-fucosyltransferase from cultured human skin fibroblasts. Requirement of a specific biantennary oligosaccharide as substrate. J Biol Chem 266(32): 21572- 21577.
72. Walker MR, Lund J, Thompson KM, Jefferis R. 1989. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 259(2): 347- 353.
73. Walsh G, Jefferis R. 2006. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24(10): 1241- 1252.
74. Wilson JR, Williams D, Schachter H. 1976. The control of glycoprotein synthesis: N-acetylglucosamine linkage to a mannose residue as a signal for the attachment of L-fucose to the asparagine-linked N-acetylglucosamine residue of glycopeptide from alpha1-acid glycoprotein. Biochem Biophys Res Commun 72(3): 909- 916.
75. Wright A, Morrison SL. 1994. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 180(3): 1087- 1096.
76. Wright A, Morrison SL. 1998. Effect of C2-associated carbohydrate structure on Ig effector function: Studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 160(7): 3393- 3402.
77. Wright A, Sato Y, Okada T, Chang K, Endo T, Morrison S. 2000. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10(12): 1347- 1355.
78. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87(5): 614- 622.
79. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T. 2008. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99(3): 652- 665.